Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22340659 | 0.90 | BCHE (0.52) | BCHEHTTSMN1; SMN2APLNRSLC6A4 | |
| SCHEMBL20870840 | 0.88 | BCHE (0.52) | BCHEHTTSMN1; SMN2LMNA | |
| SCHEMBL22340949 | 0.86 | BCHE (0.62) | BCHESMN1; SMN2AOC3TAS2R14LMNA | |
| SCHEMBL20871279 | 0.85 | APLNR (0.49) | BCHEAPLNRSLC6A4AOC3TAS2R14 | |
| SCHEMBL13286274 | 0.85 | BCHE (0.46) | BCHETAS2R14 | |
| SCHEMBL20871191 | 0.82 | SMN1; SMN2 (0.45) | BCHEHTTSMN1; SMN2APLNRSLC6A4 | |
| SCHEMBL22340957 | 0.78 | MAPT (0.55) | HTTSMN1; SMN2TAS2R14L3MBTL1LMNA | |
| SCHEMBL20871412 | 0.78 | HTT (0.42) | HTTSMN1; SMN2APLNRSLC6A4PYCR1 | |
| SCHEMBL22340675 | 0.77 | BCHE (0.58) | BCHESMN1; SMN2AOC3TAS2R14LMNA | |
| SCHEMBL23058158 | 0.76 | BCHE (0.58) | BCHESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034646-B2 | Method for the synthesis of unsymmetrical tertiary amines | Universite Paris-Saclay (FR) | 2021-06-15 | — | — | US | disclosed |
| US-20200255369-A1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | Universite Paris-Saclay (FR) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255369-A1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | ADH1C, ADH1A, ADH5 | BCHE 307/4885HTT 2812/4885SMN1; SMN2 2857/4885 |
| US-11034646-B2 | Method for the synthesis of unsymmetrical tertiary amines | ADH1C, PNMT, ADH1A | BCHE 256/4885HTT 2436/4885SMN1; SMN2 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.